BioSpace

Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’

The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglutide in the Asian country.

By BioSpace

1 min read
Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights